Top

Molecular Cancer

Published in:

Open Access 01-12-2010 | Research

PKCα expression is a marker for breast cancer aggressiveness

Authors: Gry Kalstad Lønne, Louise Cornmark, Iris Omanovic Zahirovic, Göran Landberg, Karin Jirström, Christer Larsson

Published in: Molecular Cancer | Issue 1/2010

Abstract

Background

Protein kinase C (PKC) isoforms are potential targets for breast cancer therapy. This study was designed to evaluate which PKC isoforms might be optimal targets for different breast cancer subtypes.

Results

In two cohorts of primary breast cancers, PKCα levels correlated to estrogen and progesterone receptor negativity, tumor grade, and proliferative activity, whereas PKCδ and PKCε did not correlate to clinicopathological parameters. Patients with PKCα-positive tumors showed poorer survival than patients with PKCα-negative tumors independently of other factors. Cell line studies demonstrated that PKCα levels are high in MDA-MB-231 and absent in T47D cells which proliferated slower than other cell lines. Furthermore, PKCα silencing reduced proliferation of MDA-MB-231 cells. PKCα inhibition or downregulation also reduced cell migration in vitro.

Conclusions

PKCα is a marker for poor prognosis of breast cancer and correlates to and is important for cell functions associated with breast cancer progression.

Available only for authorised users

Vargo-Gogola T, Rosen JM: Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007, 7: 659-672. 10.1038/nrc2193CrossRefPubMed

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn van de M, Jeffrey SS: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098PubMedCentralCrossRefPubMed

Newton AC: Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev. 2001, 101: 2353-2364. 10.1021/cr0002801CrossRefPubMed

Ways DK, Kukoly CA, deVente J, Hooker JL, Bryant WO, Posekany KJ, Fletcher DJ, Cook PP, Parker PJ: MCF-7 breast cancer cells transfected with protein kinase C- α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest. 1995, 95: 1906-1915. 10.1172/JCI117872PubMedCentralCrossRefPubMed

Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA: Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Cα. Clin Cancer Res. 2001, 7: 3156-3165.PubMed

Tonetti DA, Chisamore MJ, Grdina W, Schurz H, Jordan VC: Stable transfection of protein kinase C α cDNA in hormone-dependent breast cancer cell lines. Br J Cancer. 2000, 83: 782-791. 10.1054/bjoc.2000.1326PubMedCentralCrossRefPubMed

Tonetti DA, Morrow M, Kidwai N, Gupta A, Badve S: Elevated protein kinase C α expression may be predictive of tamoxifen treatment failure. Br J Cancer. 2003, 88: 1400-1402. 10.1038/sj.bjc.6600923PubMedCentralCrossRefPubMed

Assender JW, Gee JM, Lewis I, Ellis IO, Robertson JF, Nicholson RI: Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol. 2007, 60: 1216-1221. 10.1136/jcp.2006.041616PubMedCentralCrossRefPubMed

Gill PK, Gescher A, Gant TW: Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta. Eur J Biochem. 2001, 268: 4151-4157. 10.1046/j.1432-1327.2001.02326.xCrossRefPubMed

10.

Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel WC, Obeid LM, Fine RL, Hannun YA: Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKCα. J Biol Chem. 1993, 268: 658-664.PubMed

11.

Roychowdhury D, Lahn M: Antisense therapy directed to protein kinase C-α (Affinitak, LY900003/ISIS 3521): potential role in breast cancer. Semin Oncol. 2003, 30: 30-33.CrossRefPubMed

12.

Ainsworth PD, Winstanley JH, Pearson JM, Bishop HM, Garrod DR: Protein kinase C α expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma. Eur J Cancer. 2004, 40: 2269-2273. 10.1016/j.ejca.2004.06.027CrossRefPubMed

13.

Kerfoot C, Huang W, Rotenberg SA: Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase Cα. J Histochem Cytochem. 2004, 52: 419-422.CrossRefPubMed

14.

Zeidan YH, Wu BX, Jenkins RW, Obeid LM, Hannun YA: A novel role for protein kinase Cδ-mediated phosphorylation of acid sphingomyelinase in UV light-induced mitochondrial injury. Faseb J. 2008, 22: 183-193. 10.1096/fj.07-8967comCrossRefPubMed

15.

McCracken MA, Miraglia LJ, McKay RA, Strobl JS: Protein kinase C δ is a prosurvival factor in human breast tumor cell lines. Mol Cancer Ther. 2003, 2: 273-281.PubMed

16.

Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K, Reddy KB: Upregulation of PKC- δ contributes to antiestrogen resistance in mammary tumor cells. Oncogene. 2005, 24: 3166-3176. 10.1038/sj.onc.1208502CrossRefPubMed

17.

Alonso-Escolano D, Medina C, Cieslik K, Radomski A, Jurasz P, Santos-Martinez MJ, Jiffar T, Ruvolo P, Radomski MW: Protein kinase C δ mediates platelet-induced breast cancer cell invasion. J Pharmacol Exp Ther. 2006, 318: 373-380. 10.1124/jpet.106.103358CrossRefPubMed

18.

Kiley SC, Clark KJ, Duddy SK, Welch DR, Jaken S: Increased protein kinase Cδ in mammary tumor cells: relationship to transformtion and metastatic progression. Oncogene. 1999, 18: 6748-6757. 10.1038/sj.onc.1203101CrossRefPubMed

19.

Kiley SC, Clark KJ, Goodnough M, Welch DR, Jaken S: Protein kinase C δ involvement in mammary tumor cell metastasis. Cancer Res. 1999, 59: 3230-3238.PubMed

20.

Grossoni VC, Falbo KB, Kazanietz MG, de Kier Joffe ED, Urtreger AJ: Protein kinase C δ enhances proliferation and survival of murine mammary cells. Mol Carcinog. 2007, 46: 381-390. 10.1002/mc.20287CrossRefPubMed

21.

Lønne GK, Masoumi KC, Lennartsson J, Larsson C: Protein kinase Cδ supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway. J Biol Chem. 2009, 284: 33456-33465. 10.1074/jbc.M109.036186PubMedCentralCrossRefPubMed

22.

Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN, Merajver SD: Protein kinase C ε is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res. 2005, 65: 8366-8371. 10.1158/0008-5472.CAN-05-0553CrossRefPubMed

23.

Lu D, Sivaprasad U, Huang J, Shankar E, Morrow S, Basu A: Protein kinase C- ε protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation. Apoptosis. 2007.

24.

Sivaprasad U, Shankar E, Basu A: Downregulation of Bid is associated with PKCε-mediated TRAIL resistance. Cell Death Differ. 2007, 14: 851-860. 10.1038/sj.cdd.4402077CrossRefPubMed

25.

Lu D, Huang J, Basu A: Deregulation of PKB influences antiapoptotic signaling by PKC in breast cancer cells. Int J Oncol. 2004, 25: 671-676.PubMed

26.

Zeidman R, Lofgren B, Pahlman S, Larsson C: PKCε, via its regulatory domain and independently of its catalytic domain, induces neurite-like processes in neuroblastoma cells. J Cell Biol. 1999, 145: 713-726. 10.1083/jcb.145.4.713PubMedCentralCrossRefPubMed

27.

Nielsen NH, Arnerlov C, Emdin SO, Landberg G: Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to oestrogen receptor status. Br J Cancer. 1996, 74: 874-880.PubMedCentralCrossRefPubMed

28.

Nielsen NH, Emdin SO, Cajander J, Landberg G: Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene. 1997, 14: 295-304. 10.1038/sj.onc.1200833CrossRefPubMed

29.

Roos G, Nilsson P, Cajander S, Nielsen NH, Arnerlov C, Landberg G: Telomerase activity in relation to p53 status and clinico-pathological parameters in breast cancer. Int J Cancer. 1998, 79: 343-348. 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-VCrossRefPubMed

30.

Svensson S, Jirstrom K, Ryden L, Roos G, Emdin S, Ostrowski MC, Landberg G: ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene. 2005, 24: 4370-4379. 10.1038/sj.onc.1208626CrossRefPubMed

31.

Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirstrom K: Oestrogen receptors α and β show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol. 2008, 61: 197-203. 10.1136/jcp.2006.040378CrossRefPubMed

32.

Helczynska K, Larsson A-M, Holmquist Mengelbier L, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirstrom K: Hypoxia-inducible factor-2α correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res. 2008, 68: 9212-9220. 10.1158/0008-5472.CAN-08-1135CrossRefPubMed

33.

Raghunath A, Ling M, Larsson C: The catalytic domain limits the translocation of protein kinase C α in response to increases in Ca2+ and diacylglycerol. Biochem J. 2003, 370: 901-912. 10.1042/BJ20021420PubMedCentralCrossRefPubMed

34.

Malyuchik SS, Kiyamova RG: Medullary breast carcinoma. Exp Oncol. 2008, 30: 96-101.PubMed

35.

Cameron AJ, Procyk KJ, Leitges M, Parker PJ: PKC α protein but not kinase activity is critical for glioma cell proliferation and survival. Int J Cancer. 2008, 123: 769-779. 10.1002/ijc.23560CrossRefPubMed

36.

Ng T, Shima D, Squire A, Bastiaens PI, Gschmeissner S, Humphries MJ, Parker PJ: PKCα regulates β1 integrin-dependent cell motility through association and control of integrin traffic. Embo J. 1999, 18: 3909-3923. 10.1093/emboj/18.14.3909PubMedCentralCrossRefPubMed

37.

Abeyweera TP, Chen X, Rotenberg SA: Phosphorylation of α 6-tubulin by protein kinase Cα activates motility of human breast cells. J Biol Chem. 2009.

38.

Frankel LB, Lykkesfeldt AE, Hansen JB, Stenvang J: Protein Kinase C α is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res Treat. 2007, 104: 165-179. 10.1007/s10549-006-9399-1CrossRefPubMed

39.

Lin X, Yu Y, Zhao H, Zhang Y, Manela J, Tonetti DA: Overexpression of PKCα is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis. 2006, 27: 1538-1546. 10.1093/carcin/bgl002CrossRefPubMed

40.

Yde CW, Gyrd-Hansen M, Lykkesfeldt AE, Issinger OG, Stenvang J: Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. Mol Cancer Ther. 2007, 6: 1869-1876. 10.1158/1535-7163.MCT-07-0072CrossRefPubMed

41.

de Vente JE, Kukoly CA, Bryant WO, Posekany KJ, Chen J, Fletcher DJ, Parker PJ, Pettit GJ, Lozano G, Cook PP: Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest. 1995, 96: 1874-1886. 10.1172/JCI118233PubMedCentralCrossRefPubMed

42.

Parsons M, Keppler MD, Kline A, Messent A, Humphries MJ, Gilchrist R, Hart IR, Quittau-Prevostel C, Hughes WE, Parker PJ, Ng T: Site-directed perturbation of protein kinase C- integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol. 2002, 22: 5897-5911. 10.1128/MCB.22.16.5897-5911.2002PubMedCentralCrossRefPubMed

Title: PKCα expression is a marker for breast cancer aggressiveness
Authors: Gry Kalstad Lønne
Louise Cornmark
Iris Omanovic Zahirovic
Göran Landberg
Karin Jirström
Christer Larsson
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-9-76

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer

MiTF links Erk1/2 kinase and p21CIP1/WAF1 activation after UVC radiation in normal human melanocytes and melanoma cells

SOX11 expression correlates to promoter methylation and regulates tumor growth in hematopoietic malignancies

Axin downregulates TCF-4 transcription via β-catenin, but not p53, and inhibits the proliferation and invasion of lung cancer cells

5-ALA mediated photodynamic therapy induces autophagic cell death via AMP-activated protein kinase

Keynote webinar | Spotlight on antibody–drug conjugates in cancer